The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | The advances and limitations of genetic testing for actionable mutations
Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, talks on the advances in genetic testing for actionable mutations, including in technologies that can provide multiple mutational analysis. The limitations of biomarker testing are additionally discussed, including the lack of accessibility to biomarker analysis for some patients. This interview took place during the virtual European Lung Cancer Congress 2022.
